Top 15 Life Science VC (Venture Capital) Funds in Australia in July 2025
A list of 15 VC (Venture Capital) funds that invest in Life science startups based in Australia. We rank investors based on the number of investments they made in Life science companies from Australia. We update this investor list every month.Top 15 Life Science VC (Venture Capital) Funds in Australia in July 2025
Investor | Life Science Australia investments |
---|---|
Main Sequence Ventures | 2 |
Medical Research Commercialisation Fund (MRCF) | 1 |
Flintco, LLC | 1 |
Uniseed | 1 |
Bioplatforms Australia | 1 |
Catalio Capital Management | 1 |
AbbVie Biotech Ventures | 1 |
OneVentures | 1 |
Alium Capital | 1 |
Breakthrough Victoria | 1 |
Churchill Asset Management | 1 |
The March Group | 1 |
Skalata | 1 |
Tin Alley Ventures | 1 |
Uniseed Ventures | 1 |
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Seed, Series A, Series B
- Australia, United States, Philippines
Portfolio highlights
- Levur — Levur produces oils inspired by nature, without the environmental impact. Our vision is a future where reliance on unsustainable plant and animal oils like Palm Oil is drastically reduced, mitigating environmental impacts. We are collaborating with large consumer goods manufacturers to make this a
- Arkeus — Arkeus is a leader in the fusion of optics and autonomy. Our wide area autonomous optical systems are deployed to conduct Search, Intelligence, Surveillance and Reconnaissance in a range of operating environments.
- QuintessenceLabs — Quantum cyberattacks can break current encryption in minutes! Get protected with QuintessenceLabs quantum key distribution, generation, and management.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Glyscend — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Flintco provides innovative construction solutions with an unrelenting focus on quality, safety, cost and schedule.
Show more
Investment focus
- Real Estate, Life Science, Property Management
- Seed
- Australia
Portfolio highlights
- LCG Capital Management — LCG Capital Management delivers expert real estate solutions, from property management in St. Louis, MO, to asset management & development.
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Series A, Seed, Series B
- Australia, United States, United Kingdom
Portfolio highlights
- Diraq — Diraq uses spins in silicon quantum dots as qubits. Diraq's qubits are compatible with existing CMOS processes and can fit billions of qubits on a single chip. To transform our world, quantum computers need billions of qubits and Diraq has the IP, the team and the plan to get there.
- Celosia Therapeutics — The Celosia Therapeutics approach is the result of advances in gene therapies and a better understanding of the molecular pathways that contribute to neurodegenerative diseases.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Bioplatforms Australia is a non-profit entity that supports life science research in genomic, proteomics, metabolomics, and bioinformatics.
Show more
Investment focus
- AgTech, Farming, Agriculture
- Pre-Seed
- Australia
Portfolio highlights
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Israel, Switzerland
Portfolio highlights
- Visby Medical — Visby Medical is a medical diagnostics company with portable PCR testing technology for both clinical and mobile laboratory settings.
- Character Biosciences — Biopharmaceutical research and development company that's an affiliate of Clover Health
- Imbria Pharmaceuticals — Imbria is a clinical-stage, cardio-metabolic company developing innovative cellular energy enhancing therapies for the treatment of cardiovascular disorders
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, Italy
Portfolio highlights
- Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
- Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Debt Financing, Funding Round
- Australia, United States, Israel
Portfolio highlights
- Hometime — At Hometime, we provide Airbnb property management solutions for homeowners and rental management business owners that help them scale and earn more.
- StrongDM — Manage access to any server, database, or Kubernetes instance in minutes. Fully auditable, replayable, secure, and drag-and-drop easy.
- Employment Hero — Employment Hero operates as an online human resource platform for small and medium-sized businesses. Its cloud-based HR platform combines HR software, financial services, scheduling, and payroll tools, as well as employee benefits, providing growing companies with an intuitive, affordable way to manage essential employee information and HRprocesses. The company aims to become the employment platform of choice for employers and employees in Australia and beyond, by providing free, easy-to-use HR software that employers love to use, and access to far greater benefits for all employees.Employment Hero was founded in 2014 and is headquartered in Sydney New South Wales.
Alium Capital focuses on listed and unlisted technology investments to generate out-sized returns. The company invests in technology, innovation, and early-stage businesses, all the way through to publicly listed assets.
It specializes in the fields of finance, investing, innovation, and capital.Alium Capital was founded in 2016 andheadquartered in Sydney, New South Wales.
Show more
Investment focus
- Software, Financial Services, FinTech
- Series A, Series B, Seed
- Australia, United States, Singapore
Portfolio highlights
- Beforepay — Beforepay understands that traditional pay cycles are a form of financial stress. So we set out to find a better way, giving Australians the control and confidence that comes with managing your own money, on your terms.That’s why we created Pay On Demand™ - a service that allows you to access the money you have earned at work, when you choose todo so. After all, it is yours!The app also automatically predicts when your bills are due, shows you how much is OK for you to spend, and automatically creates budgets for you, effortlessly.
- Academy Xi — At Academy Xi, we help APAC's largest and most sophisticated organisations optimise performance with concise, actionable training solutions.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,293,506 freelance designers compete to create amazing designs for your business. Start Today!
The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.
Show more
Investment focus
- Manufacturing, Health Care, Software
- Funding Round, Series A, Seed
- Australia, United States, Philippines
Portfolio highlights
- EntroMat — EntroMat is a pioneering deep-tech startup transforming the metal powder industry through the advancement of high entropy material (HEM) powders.
- Umps Health — Umps offers a 24/7 personal alarm that helps you live independently with peace of mind. Easy to use, always connected.
- Quantum Brilliance — Quantum Brilliance builds room temperature quantum computers powered by synthetic diamond, enabling applications in everyday computing, including edge and massively parrellelized computing.
Churchill is a leading capital provider for private equity-owned, middle market companies. We provide first lien, unitranche, second lien and mezzanine debt, in addition to equity co-investments, secondary solutions and private equity fund commitments.
Show more
Investment focus
- Health Care, Pet, Dental
- Debt Financing, Private Equity
- United States
Portfolio highlights
- Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
- Mosaic Dental Collective — Mosaic Dental Collective provides administrative and business operations support to dental practices. They are a multi-specialty group where doctors make decisions and are supported by an experienced professional management team.
- Heartland Veterinary Partners — Heartland Veterinary Partners purchases practices, providing operational support for payroll, HR, marketing, and more. Veterinarians can focus on patient care.
A venture capital fund platform committed to supporting and investing in entrepreneurs and companies developing and bringing exponential technologies to food, health and sustainability. March's investment strategy involves becoming recognized as the leading investor in critical and transformative technology solutions, and aims to achieve thisby investing into companies and funds that focus on developing core intellectual property around game-changing sustainable solutions that are aligned with globally relevant sustainability trends and benefits.
Show more
Investment focus
- SaaS, Energy, Retail
- Seed, Series A, Series C
- United States
Portfolio highlights
- Digestiva — We amplifye Protein.
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.
Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.
Show more
Investment focus
- Software, Information Technology, Marketplace
- Pre-Seed, Seed
- Australia, United States, United Kingdom
Portfolio highlights
- TALY — TALY is a platform that is designed to find, manage and retain employees from both perfromance and personality for business development.
- Viewa — Viewa is an augmented reality(AR) content publishing platform that brings print media such as magazines to life in 3D.
- Enrola — Looking for online training courses? Discover the perfect course for you with our easy course advisor quiz. Get individual guidance and apply directly.
Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.
Show more
Investment focus
- Medical, Health Care, Therapeutics
- Pre-Seed
- Australia
Portfolio highlights
- Cell Bauhaus — Cell Bauhaus uses mathematical and computer modeling to understand, predict, and modify living cell behavior, aiming to expedite sustainable solutions to humanity's pressing issues.
- Remagine Labs — Remagine Labs is revolutionizing healthcare with a bluetooth-connected, wearable electro-pharmaceutical that provide patient-centered care and consistent drug administration, giving healthcare customers peace of mind all over the world.
- Psychae Therapeutics — Psychae Therapeutics develop innovative pharmaceutical grade DMT-based medicines and therapies aiming to transform the lives of those facing some of the most prolific and insidious mental illnesses
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more
Investment focus
- Biotechnology, Manufacturing, Health Care
- Series A, Seed, Funding Round
- Australia, United States, United Kingdom
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Investors by industry
Consumer
Proptech
Impact
Climate
Gaming
Biotech
FinTech
Marketplace
Community
Health Care
Hardware
Energy
Artificial intelligence
Google
EdTech
Sustainability
Venture Capital
Real Estate
Photography
Music
Art
Wellness
Franchise
Clean Energy
Mobile
Local
Digital Media
Legal
Android
eSports
Enterprise Software
Education
Sports
Manufacturing
Email
Medical
Social Network
Social Media
Internet
Construction
Hospitality
Platforms
Biotechnology
Cannabis
B2B
Mobile Advertising
Travel
Fitness
Recruiting
Financial Services
Crowdfunding
Social
Medical Device
Automotive
Wine And Spirits
CleanTech
Big Data
Mobile Apps
Transportation
InsurTech
Enterprise
Payments
Finance
Organic Food
LGBT
Food and Beverage
Web3
Infrastructure
Retail
Beauty
Publishing
Fashion
Oil and Gas
Video Games
Life Science
Theatre
Film
Non Profit
Renewable Energy
SaaS
Sporting Goods
Restaurants
Celebrity
Software
Social Impact
Cryptocurrency
Machine Learning
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
Canada
Germany
United Kingdom
Ireland
South Korea
India
Australia
New Zealand
United States
Middle East
Brazil
LATAM
Qatar
Indonesia
Asia
Europe
Spain
South Africa
Singapore
Armenia
Saudi Arabia
Sri Lanka
China
Africa
Oceania
Japan
Vietnam
Belarus
Chile
Belgium
Hong Kong
Finland
Ghana
Georgia
Ethiopia
Gibraltar
Faroe Islands
Denmark
Kuwait
Malta
Morocco
Nicaragua
Mali
Lithuania
Peru
Lebanon
Jersey
Norway
Myanmar
Mauritius
Liberia
Mexico
Malaysia
Liechtenstein
Philippines
Italy
Israel
Panama
Poland
Senegal
Sierra Leone
Egypt
Tunisia
Togo
Serbia
Turkey
San Marino
Thailand
Uzbekistan
Taiwan
Sweden
Tanzania
Slovenia
El Salvador
Portugal
Tajikistan
Ukraine
Estonia
Puerto Rico
Uganda
Venezuela
Uruguay
Zambia
Zimbabwe
Rwanda
Russian Federation
Dominican Republic
Costa Rica
Nigeria
Hungary
Iraq
Azerbaijan
Bahamas
Iceland
Namibia
United Arab Emirates
Greece
Jamaica
Honduras
Barbados
Bolivia
Isle of Man
Croatia
Luxembourg
Belize
Albania
Bahrain
Pakistan
Czech Republic
Algeria
Ecuador
Bulgaria
Bermuda
France
Grenada
Jordan
Bangladesh
Argentina
Romania
Kazakhstan
Kenya
Cayman Islands
Cambodia
Latvia
Cyprus
Oman
Cameroon
Austria
Switzerland
Colombia
Guatemala
Seychelles
Marshall Islands
VC (Venture Capital) Funds in Australia by industry
Transportation
Health Care
Consumer
Climate
Biotech
Energy
SaaS
Proptech
Community
Marketplace
Hardware
Restaurants
Crowdfunding
Venture Capital
Mobile Apps
Life Science
Oil and Gas
Real Estate
Finance
Cryptocurrency
Payments
InsurTech
Food and Beverage
Video Games
Medical
Social Network
Email
Wellness
Medical Device
Social Media
Digital Media
Art
Manufacturing
Music
Internet
Mobile
Android
Blockchain
FinTech
Enterprise
Legal
Construction
Fitness
Software
eSports
Hospitality
CleanTech
Automotive
Biotechnology
Travel
Cannabis
Retail
Social
Fashion
Web3
Beauty
B2B
Big Data
Publishing
Clean Energy
Financial Services
Education
Infrastructure
Non Profit
Wine And Spirits
Sports
Impact
EdTech
Artificial intelligence
Gaming
Renewable Energy
Agriculture (agtech)
Platforms
Machine Learning
Media (entertainment)
Recruiting
Sustainability
Sporting Goods
Social Impact
Enterprise Software